Effect of gender on late-onset multiple sclerosis

Multiple Sclerosis Journal

Volumn 18, Issue 10, 2012, Pages 1472-1479

  Bove, Riley M ^a   Healy, Brian ^a,b   Augustine, Ann ^a   Musallam, Alexander ^a   Gholipour, Taha ^a   Chitnis, Tanuja ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

disability; female; geriatrics; menopause; multiple sclerosis; progression

Indexed keywords

ADULT; ADULT ONSET MULTIPLE SCLEROSIS; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISABILITY; DISEASE COURSE; ETHNICITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; LATE ONSET MULTIPLE SCLEROSIS; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; MULTIPLE SCLEROSIS; RACE; SEX DIFFERENCE; VERY LATE ONSET MULTIPLE SCLEROSIS;

EID: 84867010020     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512438236     Document Type: Article

References (51)

1. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci. 2001 ; 22: 117-139
2. Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006 ; 13: 700-722
3. Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 2006 ; 5: 932-936
4. Ramagopalan SV, Valdar W, Criscuoli M, et al. Age of puberty and the risk of multiple sclerosis: a population based study. Eur J Neurol. 2009 ; 16: 342-347
5. Vukusic S, Confavreux C. Pregnancy and multiple sclerosis: the children of PRIMS. Clin Neurol Neurosurg. 2006 ; 108: 266-270
6. Gold SM, Voskuhl RR. Estrogen and testosterone therapies in multiple sclerosis. Prog Brain Res. 2009 ; 175: 239-251
7. Papenfuss TL, Powell ND, McClain MA, et al. Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity. J Immunol. 2011 ; 186: 3346-3355
8. Voskuhl RR, Palaszynski K. Sex hormones in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neuroscientist. 2001 ; 7: 258-270
9. Nicot A. Gender and sex hormones in multiple sclerosis pathology and therapy. Front Biosci. 2009 ; 14: 4477-4515
10. Mowry EM, Pesic M, Grimes B, Deen SR, Bacchetti P, Waubant E. Clinical predictors of early second event in patients with clinically isolated syndrome. J Neurol. 2009 ; 256: 1061-1066
11. Ramagopalan SV, Yee IM, Dyment DA, et al. Parent-of-origin effect in multiple sclerosis: observations from interracial matings. Neurology. 2009 ; 73: 602-605
12. Chitnis T, Glanz B, Jaffin S, Healy B. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler. 2009 ; 15: 627-631
13. Ghezzi A, Deplano V, Faroni J, et al. Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler. 1997 ; 3: 43-46
14. Ruggieri M, Iannetti P, Polizzi A, Pavone L, Grimaldi LM. Multiple sclerosis in children under 10 years of age. Neurol Sci. 2004 ; 25 (Suppl 4). S326 - S335
15. Chitnis T. Pediatric multiple sclerosis. Neurologist. 2006 ; 12: 299-310
16. Phadke JG. Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. Brain. 1990 ; 113 (Pt 6). 1597-1628
17. Delalande S, De Seze J, Ferriby D, Stojkovic T, Vermersch P. Late onset multiple sclerosis. Rev Neurol (Paris). 2002 ; 158: 1082-1087
18. Polliack ML, Barak Y, Achiron A. Late-onset multiple sclerosis. J Am Geriatr Soc. 2001 ; 49: 168-171
19. Tremlett H, Devonshire V. Is late-onset multiple sclerosis associated with a worse outcome?. Neurology. 2006 ; 67: 954-959
20. Noseworthy J, Paty D, Wonnacott T, Feasby T, Ebers G. Multiple sclerosis after age 50. Neurology. 1983 ; 33: 1537-1544
21. Azzimondi G, Stracciari A, Rinaldi R, D'Alessandro R, Pazzaglia P. Multiple sclerosis with very late onset: report of six cases and review of the literature. Eur Neurol. 1994 ; 34: 332-336
22. Hooge JP, Redekop WK. Multiple sclerosis with very late onset. Neurology. 1992 ; 42: 1907-1910
23. White AD, Swingler RJ, Compston DA. Features of multiple sclerosis in older patients in South Wales. Gerontology. 1990 ; 36: 159-164
24. Lyon-Caen O, Izquierdo G, Marteau R, Lhermitte F, Castaigne P, Hauw JJ. Late onset multiple sclerosis. A clinical study of 16 pathologically proven cases. Acta Neurol Scand. 1985 ; 72: 56-60
25. Runmarker B, Andersson C, Oden A, Andersen O. Prediction of outcome in multiple sclerosis based on multivariate models. J Neurol. 1994 ; 241: 597-604
26. Stankoff B, Mrejen S, Tourbah A, et al. Age at onset determines the occurrence of the progressive phase of multiple sclerosis. Neurology. 2007 ; 68: 779-781
27. Kantarci O, Siva A, Eraksoy M, et al. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology. 1998 ; 51: 765-772
28. Tortorella C, Bellacosa A, Paolicelli D, et al. Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis. J Neurol Sci. 2005 ; 239: 95-99
29. de Seze J, Delalande S, Michelin E, et al. Brain MRI in late-onset multiple sclerosis. Eur J Neurol. 2005 ; 12: 241-244
30. Healy BC, Engler D, Gholipour T, Weiner H, Bakshi R, Chitnis T. Accounting for disease-modifying therapy in models of clinical progression in multiple sclerosis. J Neurol Sci. 2011 ;:
31. Gholipour T, Healy B, Baruch NF, Weiner HL, Chitnis T. Demographic and clinical characteristics of malignant multiple sclerosis. Neurology. 2011 ; 76: 1996-2001
32. Ann Neurol. Polman CH Reingold SC Edan G, ed. 2005: 840-846.
33. Dean G, Kurtzke JF. A critical age for the acquisition of multiple sclerosis. Trans Am Neurol Assoc. 1970 ; 95: 232-233
34. Kis B, Rumberg B, Berlit P. Clinical characteristics of patients with late-onset multiple sclerosis. J Neurol. 2008 ; 255: 697-702
35. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996 ; 46: 907-911
36. Kurtzke J. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology. 1983 ; 33: 1444-1452
37. Finkelstein DM. A proportional hazards model for interval-censored failure time data. Biometrics. 1986 ; 42: 845-854
38. Martinelli V, Rodegher M, Moiola L, Comi G. Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis. Neurol Sci. 2004 ; 25 (Suppl 4). S350-355
39. Sim FJ, Zhao C, Penderis J, Franklin RJ. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J Neurosci. 2002 ; 22: 2451-2459
40. Lu T, Pan Y, Kao SY, et al. Gene regulation and DNA damage in the ageing human brain. Nature. 2004 ; 429: 883-891
41. Filippi M, Wolinsky JS, Sormani MP, Comi G. Enhancement frequency decreases with increasing age in relapsing-remitting multiple sclerosis. Neurology. 2001 ; 56: 422-423
42. Gold SM, Voskuhl RR. Estrogen treatment in multiple sclerosis. J Neurol Sci. 2009 ; 286: 99-103
43. Ramagopalan SV, Byrnes JK, Orton SM, et al. Sex ratio of multiple sclerosis and clinical phenotype. Eur J Neurol. 2010 ; 17: 634-637
44. Kato I, Toniolo P, Akhmedkhanov A, Koenig KL, Shore R, Zeleniuch-Jacquotte A. Prospective study of factors influencing the onset of natural menopause. J Clin Epidemiol. 1998 ; 51: 1271-1276
45. Wundes A, Amtmann D, Brown T, Christian S. Menopause in women with multiple sclerosis. International Journal of MS Care. 2011 ; 13: 47
46. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Does multiple sclerosis-associated disability differ between races?. Neurology. 2006 ; 66: 1235-1240
47. Cree BA, Reich DE, Khan O, et al. Modification of multiple sclerosis phenotypes by African ancestry at HLA. Arch Neurol. 2009 ; 66: 226-233
48. Zuvich RL, McCauley JL, Pericak-Vance MA, Haines JL. Genetics and pathogenesis of multiple sclerosis. Semin Immunol. 2009 ; 21: 328-333
49. Benedict RH, Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol. 2011 ; 7: 332-342
50. Greer JM, McCombe PA. Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms. J Neuroimmunol. 2011 ; 234: 7-18
51. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011 ; 476: 214-219